Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 11/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.38 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326583 | 0.87 | PTGES (0.39) | PTGESCYP2C9KDM4EHTTJAK2 | |
| SCHEMBL29326574 | 0.86 | FASN (0.42) | PTGESCYP2C9KDM4EHTTNPEPPS | |
| SCHEMBL29326451 | 0.86 | KDM4E (0.45) | PTGESCYP2C9KDM4EHTTNPEPPS | |
| SCHEMBL29326437 | 0.86 | KDM4E (0.50) | PTGESCYP2C9KDM4EHTTNPEPPS | |
| SCHEMBL29326751 | 0.85 | PTGES (0.41) | PTGESCYP2C9KDM4EHTTJAK2 | |
| SCHEMBL29326363 | 0.83 | TNKS2 (0.50) | PTGESCYP2C9KDM4EHTTNPEPPS | |
| SCHEMBL29326689 | 0.82 | PTGES (0.48) | PTGESCYP2C9KDM4EHTTNPEPPS | |
| SCHEMBL29326448 | 0.82 | ITGA4 (0.42) | PTGESCYP2C9KDM4EHTTJAK2 | |
| SCHEMBL29326609 | 0.82 | KDM4E (0.43) | PTGESCYP2C9KDM4EHTTNPEPPS | |
| SCHEMBL27380550 | 0.81 | KDM4E (0.38) | PTGESCYP2C9KDM4EHTTNPEPPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | PTGES 1477/4885CYP2C9 263/4885KDM4E 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.